Two Sigma Advisers
PRLD icon

Two Sigma Advisers’s Prelude Therapeutics PRLD Stock Holding History

Two Sigma Advisers’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-237,300
Closed -$688K – 1618
2025
Q4 		$688K Buy
237,300
+14,600
+7% +$24.6K ﹤0.01% 1663
2025
Q3 		$321K Sell
222,700
-2,300
-1% -$2.31K ﹤0.01% 1953
2025
Q2 		$182K Sell
225,000
-35,400
-14% -$30.7K ﹤0.01% 2137
2025
Q1 		$200K Sell
260,400
-39,600
-13% -$36.9K ﹤0.01% 2139
2024
Q4 		$383K Buy
300,000
+252,100
+526% +$335K ﹤0.01% 1879
2024
Q3 		$99.2K Sell
47,900
-3,000
-6% -$13.9K ﹤0.01% 2166
2024
Q2 		$194K Sell
50,900
-19,300
-27% -$78.5K ﹤0.01% 2223
2024
Q1 		$333K Buy
70,200
+8,400
+14% +$32.7K ﹤0.01% 2032
2023
Q4 		$264K Buy
61,800
+30,700
+99% +$93.5K ﹤0.01% 2148
2023
Q3 		$96.1K Sell
31,100
-15,700
-34% -$58.9K ﹤0.01% 2214
2023
Q2 		$211K Sell
46,800
-3,700
-7% -$22.1K ﹤0.01% 2085
2023
Q1 		$288K Sell
50,500
-24,800
-33% -$151K ﹤0.01% 2153
2022
Q4 		$455K Sell
75,300
-34,233
-31% -$219K ﹤0.01% 1921
2022
Q3 		$724K Sell
109,533
-126,167
-54% -$851K ﹤0.01% 1686
2022
Q2 		$1.23M Buy
235,700
+109,200
+86% +$556K ﹤0.01% 1477
2022
Q1 		$873K Buy
126,500
+42,200
+50% +$386K ﹤0.01% 1704
2021
Q4 		$1.05M Buy
+84,300
New +$1.37M ﹤0.01% 1542

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Advisers's PRLD Position: Q1 2026 in Review

Two Sigma Advisers sold out of Prelude Therapeutics (PRLD) in Q1 2026, closing a stake of 237,300 shares — an estimated $688K sold.

Two Sigma Advisers first reported a position in PRLD in Q4 2021 and held it in 17 quarters. The position peaked at $1.23M in Q2 2022. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Two Sigma Advisers reported no remaining Prelude Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 237,300 Prelude Therapeutics shares in Q1 2026, an estimated $688K.
  • Two Sigma Advisers first reported a position in Prelude Therapeutics in Q4 2021 and held it in 17 quarters.
  • Two Sigma Advisers's Prelude Therapeutics position peaked at $1.23M in Q2 2022.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.